AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06164717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS stimulation ON/OFF
Description: Patients who have been previously implanted with a DBS stimulator for their clinical care will be tested in two speech motor learning tasks with the stimulation ON and with the stimulation OFF.~Note that (1) patients routinely turn the stimulation OFF and back ON (examples are, for some patients, to sleep, to save battery, etc), and (2) we are not in any way evaluating the stimulator itself or its clinical effectiveness but only whether or not two forms of speech motor learning (adaptation to auditory feedback perturbation and speech sequence learning) are affected differently by having the stimulation ON or OFF.~implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF.
Study NCT04250454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTRACT
Description: The intervention will consist of four elements:~1. Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)~2. Home Activity Plan (HAP)~3. Home-based Feedback training~4. Electrical muscle stimulation~Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child.
Study NCT05480475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: On Day 1 (Treatment A1) and on Day 9 (Treatment C1) a single oral dose of 75 mg dabigatran etexilate will be administered under fasted conditions.
Study NCT05480475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: On Day 3 (Treatment A2) and on Day 11 (Treatment C2) a single oral dose of 10 mg rosuvastatin will be administered under fasted conditions.
Study NCT05480475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: On Day 7 and Day 8 (Treatment B), on Day 9 and Day 10 (Treatment C1), and on Day 11 through 14 (Treatment C2) subjects will receive 50 mg daridorexant o.d. under fasted conditions.
Study NCT04930068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low caloric diet
Description: A low-calorie diet is a structured eating plan that restricts daily caloric intake, commonly for weight loss. Following a low-calorie diet typically means consuming around 1,200 to 1,500 calories per day, which creates a calorie deficit that can lead to weight loss. A low-calorie diet can be effective, but it requires a lot of discipline to work and be safe.
Study NCT05884840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HELENA
Description: The current CV risk screening program in based using the REGICOR risk function, which is integrated in the primary care electronic health record. This risk function predicts the probability within 10 years of developing a coronary event. Those who are categorized as high risk, obtaining a 10% of probability, are candidates of receiving lipid lowering drugs and recommendations on healthy life habits.~What this intervention suggests is that, besides the REGICOR estimation, the electronic health records will also incorporate a new CV risk function, REASON. The model predicts the risk of holding a pathologic ABI score, in people aged 50-74 years old who are apparently free of CV. Patients who obtain a score ≥ 7 will undergo a PAD screening program with ABI test. If the value of the test is ≤0.9, the REGICOR, physicians will recommend indications of the Health Catalan Institute's CV and lipid Guidelines to the patients.
Study NCT05708872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing music
Description: Patients in the control group will receive a recording with relaxing music
Study NCT06176404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for SGB. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06176404 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.
Study NCT06176404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.
Study NCT04859504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial alternating current stimulation (NE Starstim)
Description: dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
Study NCT04859504 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial alternating current stimulation (NE Starstim)
Description: dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
Study NCT06229860 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: In-person interview with the study coordinator to complete study questionnaire.
Study NCT05925127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 (5μg)
Description: Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively
Study NCT05925127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2601 (5μg)
Description: The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 50 µg Matrix-M adjuvant.
Study NCT05925127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2601(5μg)
Description: The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 75 µg Matrix-M adjuvant.
Study NCT05925127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2601 (35μg)
Description: The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 50 µg Matrix-M adjuvant.
Study NCT05925127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2601(35μg)
Description: The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 75 µg Matrix-M adjuvant.
Study NCT05925127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2601(50μg)
Description: The vaccination regimen will comprise one IM injection on Day 0 at a dose of 50 µg of antigen with 100 µg Matrix-M adjuvant
Study NCT05925127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BA.4/5
Description: The bivalent BA.4/5 (or recommended mRNA vaccine at the time of the conduct of this study) Omicron subvariant/prototype licensed mRNA vaccine will be procured and stored per the manufacturer's instructions. For this vaccine group, treatment will be administered open label as a single IM injection
Study NCT05874063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis
Description: Thromboprophylaxis in addition of the standard chemotherapy
Study NCT05318794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin and Cisplatin
Description: Pressurised intraperitoneal aerosol chemotherapy
Study NCT05576155 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Compound 21
Description: Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M
Study NCT05576155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound 21 + losartan
Description: Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M.
Study NCT05814913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaCBT for psychosis
Description: The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
Study NCT05814913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted Family Intervention (CulFI) for psychosis
Description: CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
Study NCT04251819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Study NCT04251819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 5 mg
Description: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Study NCT04251819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 10mg
Description: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Study NCT06124950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender-transformative intervention
Description: A multidisciplinary team of experts, including 8-10 experts in reproductive medicine, nursing, social work, psychiatry, family law, and evidence-based medicine, will be established to support the development of the intervention.~Five 60-minutes intervention sessions will be delivered by trained nurses and social workers throughout participants' fertility treatment cycle. Intervention will be carried out at the 5 critical windows of opportunity for infertility treatment: (1) before entering the cycle; (2) during follicular monitoring; (3) before oocyte retrieval; and (4) 2 weeks after the embryo transfer; and (5) 28-30 days after the embryo transfer.~The intervention components will equip couples with educational information on health and relationship and skills obtained from interactive activities designed with an explicit focus on challenging gender stereotypes, all of which could incite reflection on sociocultural norms and gender-related power inequality.
Study NCT06152328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality applications based on mirror therapy
Description: Mirror therapy-based games will be played for 30 minutes every day for eight weeks, three days a week, for the VR group.
Study NCT06152328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Bobath therapy, walking exercises, upper extremity active exercises, and proprioceptive neuromuscular facilitation techniques will be applied three days a week for eight weeks.
Study NCT06152328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: In conventional mirror therapy, the unaffected extremities of the individuals will be positioned outside the mirror, while the affected extremities will be placed inside the mirror so that the patient cannot see them. In this way, the image of the intact hand will be transferred to the affected side and activities will be performed three days a week for eight weeks.
Study NCT06152328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo virtual reality
Description: For 8 weeks, watching the uninteractive virtual environment for 10 minutes
Study NCT05258279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion Q3W
Study NCT06545097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: Once a day for 2 days; once daily on Day1 (with Cebranopadol 200ug).
Study NCT06545097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: Once daily on Day 2 (with Cebranopadol 400 ug)
Study NCT06545097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 2 days
Study NCT04996758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab and Anlotinib
Description: Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
Study NCT06047626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Reduction Diet
Description: Sessions will be \~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.
Study NCT06047626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Health Curriculum
Description: These sessions will be matched counseling method, time spent (\~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.
Study NCT05050136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
Study NCT05050136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matched to study drug without the active pharmaceutical ingredient
Study NCT06459388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilizing Reversals and Rhythmic Stabilization
Description: 3 sets with 15 repetitions in each session, 5 days per week for 8 weeks.
Study NCT06459388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Proprioceptive Neuromuscular Facilitation
Description: The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.
Study NCT05258110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam
Study NCT05258110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study NCT05746845 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)
Study NCT05956119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling + physiotherapy (standard/usual care)
Description: same that arm descrption
Study NCT05956119 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham dry needling + physiotherapy (standard/usual care)
Description: same that arm description
Study NCT06030674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondhand cannabis emissions/smoke exposure
Description: This is an environmental exposure performed in public places where people are consuming cannabis.
Study NCT06646185 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Cups
Description: Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
Study NCT05832138 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ONLOOP program
Description: Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
Study NCT05832138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONLOOP program
Description: Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
Study NCT05934513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH009
Description: patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
Study NCT06533943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Each intervention session is divided into three different parts according to the specific aim such as warm-up (about 15 minutes) at the beginning, main exercises (about 30 minutes), and stretching and relaxation (about 15 minutes) at the end.
Study NCT05476939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.
Study NCT05476939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: Capsules of 125mg. The prescribed dose is 375mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.
Study NCT05476939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation.
Study NCT05476939 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation.
Study NCT05356806 — intervention group
Intervention type: OTHER
Intervention: Supportive periodontal and periimplant care
Description: Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space